Success Metrics

Clinical Success Rate

40.0%

Based on 2 completed trials

Completion Rate

40%(2/5)

Active Trials

0(0%)

Results Posted

100%(2 trials)

Terminated

3(60%)

Phase Distribution

Ph phase_3

40%

Ph phase_2

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

3(60.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(3)

Detailed Status

Terminated3

Completed2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

40.0%

Most Advanced

Phase 3

Trials by Phase

Phase 23 (60.0%)

Phase 32 (40.0%)

Trials by Status

terminated360%

completed240%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_2

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

NCT02719990

completedphase_3

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831

Clinical Trials (5)

Showing 5 of 5 trials

NCT02719990Phase 2

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Terminated

NCT02339090Phase 3

Long-Acting Growth Hormone in Children Compared to Daily rhGH

Completed

NCT02526420Phase 2

Versartis International Trial in Adults With Long-Acting Growth Hormone

Completed

NCT02068521Phase 2

Versartis Long-Term Safety Study of Somavaratan

Terminated

NCT03145831Phase 3

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5